Price
CHART BY
Frequently asked questions
What is Verastem's market capitalization?
The market capitalization of Verastem is $727.22M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Verastem?
Verastem's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.46. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Verastem's stock?
Currently, 9 analysts cover Verastem's stock, with a consensus target price of $15.00. Analyst ratings provide insights into the stock's expected performance.
What is Verastem's revenue over the trailing twelve months?
Over the trailing twelve months, Verastem reported a revenue of $87.53M.
What is the EBITDA for Verastem?
Verastem's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$158.65M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Verastem?
Verastem has a free cash flow of -$162.20M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Verastem have, and what sector and industry does it belong to?
Verastem employs approximately 102 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Verastem's shares?
The free float of Verastem is 81.76M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $727.22M
- EPS (TTM)
- -$2.46
- Free Float
- 81.76M
- Revenue (TTM)
- $87.53M
- EBITDA (TTM)
- -$158.65M
- Free Cashflow (TTM)
- -$162.20M
Pricing
- 1D span
- $7.896$8.387
- 52W span
- $3.43$10.81
Analyst Ratings
The price target is $15.00 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
- Employees
- 102
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- VSTM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet